
MAC.12 | TAILORx
NCT00310180
MAC.12
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) (TAILORx)
Status:
Closed to Accrual

III
Phase

Adjuvant
Line of Therapy

Early Cancer
Disease Stage

Biomarker(s)
ER+, HER2-
Investigational
Product
Tamoxifen, Anastrozole, Letrozole, or Exemestane
Treatment Arms
o Experimental: Group 1 (Oncotype DX recurrence score =< 10)
o Experimental: Group 2, Arm I (experimental)
o Active Comparator: Group 2, Arm II (standard)
o Experimental: Group 3 (Oncotype DX recurrence score >= 26)